2024
Prognostic impact of 'multi-hit' <i>versus</i> 'single-hit' <i>TP53</i> alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases.
Badar T, Nanaa A, Atallah E, Shallis R, Craver E, Li Z, Goldberg A, Saliba A, Patel A, Bewersdorf J, Duvall A, Burkart M, Bradshaw D, Abaza Y, Stahl M, Palmisiano N, Murthy G, Zeidan A, Kota V, Patnaik M, Litzow M. Prognostic impact of 'multi-hit' versus 'single-hit' TP53 alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases. Haematologica 2024, 109: 3533-3542. PMID: 38813716, PMCID: PMC11532685, DOI: 10.3324/haematol.2024.285000.Peer-Reviewed Original ResearchAcute myeloid leukemiaMyelodysplastic syndromeComplex cytogeneticsMyeloid leukemiaAllogeneic hematopoietic stem cell transplantationLower-risk myelodysplastic syndromesHematopoietic stem cell transplantationHigher-risk myelodysplastic syndromesOutcomes of SHStem cell transplantationAllo-HCTTP53 alterationsPrognostic impactMyeloid malignanciesTP53 mutationsCell transplantationFLT3-ITDIDH1 mutationMultivariate analysisSupportive careUS academic institutionsNeoplastic diseasePatientsSuperior EFSPredicting outcome
2021
Clinical effectiveness of DNA methyltransferase inhibitors and lenalidomide in older patients with refractory anemia with ring sideroblasts: a population-based study in the United States
Wang X, Zeidan AM, Wang R, Bewersdorf JP, Zhang C, Podoltsev NA, Huntington SF, Gore SD, Ma X. Clinical effectiveness of DNA methyltransferase inhibitors and lenalidomide in older patients with refractory anemia with ring sideroblasts: a population-based study in the United States. Leukemia & Lymphoma 2021, 62: 2438-2447. PMID: 33899659, DOI: 10.1080/10428194.2021.1913142.Peer-Reviewed Original ResearchConceptsPopulation-based studyDNA methyltransferase inhibitorRARS patientsRefractory anemiaRing sideroblastsRed blood cell transfusion independenceEnd Results-Medicare databaseLower-risk myelodysplastic syndromesPopulation-based cohortMethyltransferase inhibitorRBC-TIMedian durationMedian survivalOlder patientsTransfusion independenceTreatment initiationMyelodysplastic syndromeClinical effectivenessBetter survivalLenalidomideTreatment groupsPatientsRS statusOlder adultsAnemiaClinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options
Lewis R, Bewersdorf JP, Zeidan AM. Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options. Cancer Management And Research 2021, 13: 645-657. PMID: 33531837, PMCID: PMC7846829, DOI: 10.2147/cmar.s240600.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsLower-risk myelodysplastic syndromesErythropoiesis-stimulating agentsTherapeutic optionsSymptomatic anemiaMyelodysplastic syndromeRed blood cell transfusionFurther therapeutic optionsBlood cell transfusionAvailable therapeutic optionsMajority of patientsManagement of anemiaPrimary clinical goalQuality of lifeResultant cytopeniasCell transfusionFrequent transfusionsImmunosuppressive therapyClinical improvementMost patientsSelect patientsTransfusion burdenClinical managementIron overloadNovel agentsAdditional therapeutics
2020
Evolving therapies for lower-risk myelodysplastic syndromes
Bewersdorf JP, Zeidan AM. Evolving therapies for lower-risk myelodysplastic syndromes. Annals Of Hematology 2020, 99: 677-692. PMID: 32078008, DOI: 10.1007/s00277-020-03963-1.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAnemiaBlood TransfusionChelation TherapyClinical Trials as TopicCri-du-Chat SyndromeDrugs, InvestigationalForecastingHematinicsHematopoietic Stem Cell TransplantationHumansImmunosuppressive AgentsIron OverloadLenalidomideMolecular Targeted TherapyMulticenter Studies as TopicMyelodysplastic SyndromesPrecision MedicinePrognosisRisk AssessmentSeverity of Illness IndexConceptsInternational Prognostic Scoring SystemLow-risk MDS patientsMyelodysplastic syndromeMDS patientsLower-risk myelodysplastic syndromesPrognostic scoring systemRisk stratification toolAdvanced clinical testingSymptomatic anemiaStratification toolHematologic malignanciesCurrent treatmentTherapeutic approachesNew agentsNew drug approvalsTherapeutic conceptsClinical developmentPatientsClinical testingMolecular pathogenesisScoring systemTherapeutic landscapePromising agentDrug approvalGenetic features
2019
Use of immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis
Stahl M, Bewersdorf J, Giri S, Wang R, Zeidan AM. Use of immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis. Haematologica 2019, 105: 102-111. PMID: 31004015, PMCID: PMC6939518, DOI: 10.3324/haematol.2019.219345.Peer-Reviewed Original ResearchConceptsImmunosuppressive therapyProspective cohort studyMyelodysplastic syndromeClinical trialsResponse rateCohort studySystematic reviewLower-risk myelodysplastic syndromesLow-risk MDS patientsDifferent immunosuppressive regimensTransfusion independence rateAnti-thymocyte globulinComplete remission rateRelevant conference proceedingsOverall response rateTreatment of patientsAcute myeloid leukemiaHigh-quality studiesHigh response rateRandom-effects modelWeb of ScienceImmunosuppressive regimensPatient yearsRemission rateAdverse eventsTransforming growth factor (TGF)-β pathway as a therapeutic target in lower risk myelodysplastic syndromes
Bewersdorf JP, Zeidan AM. Transforming growth factor (TGF)-β pathway as a therapeutic target in lower risk myelodysplastic syndromes. Leukemia 2019, 33: 1303-1312. PMID: 30962581, DOI: 10.1038/s41375-019-0448-2.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsErythropoiesis stimulating agentsMyelodysplastic syndromeGrowth factorIneffective erythropoiesisLower-risk myelodysplastic syndromesTGF-β pathway inhibitorLR-MDS patientsFurther therapeutic optionsRisk myelodysplastic syndromesLimited therapy optionsTGF-β receptor activationPromising therapeutic approachPhysiologic conditionsTGF-β pathwayAberrant TGFImmunomodulator lenalidomideLR-MDSMyelosuppressive effectsTherapeutic optionsTherapy optionsLife impairmentAdditional potential targetsClinical dataMDS pathogenesisTherapeutic approaches